Statins in the Prevention of Contrast-Induced Nephropathy

Current Treatment Options in Cardiovascular Medicine

Volumn 17, Issue 4, 2015, Pages

  Chyou, Anthony C ^a   Thodge, Anay ^b   Feldman, Dmitriy N ^a,c   Swaminathan, Rajesh V ^a,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Contrast induced nephropathy; Prevention; Statins

Indexed keywords

ATORVASTATIN; CONTRAST MEDIUM; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANEMIA; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW;

EID: 84925324979     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-015-0375-0     Document Type: Review

References (39)

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419–28.
2. Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short and long-term implications. Semin Nephrol. 2011;31:300–9.
3. Alpert MA. Do statins reduce the risk of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary interventions? J Am Coll Cardiol. 2014;63:80–2.
4. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One. 2012;7:e34450.
5. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515–9.
6. Subramanian S, Tumlin J, Bapat B, et al. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007;10:119–34.
7. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011;151:348–53.
8. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D’Ambrosio A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial.). Am J Cardiol. 2011;108:1–7.
9. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63:62–70. This study demonstrated that short-term low-dose rosuvastatin significantly reduced risk of CIN in patients with diabetes and stage 2 CKD undergoing coronary or peripheral angiography/interventions as compared to placebo.
10. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol. 2014;63:71–9. The PRATO-ACS study showed that in statin-naïve patients presenting in ACS undergoing coronary angiography/intervention, a short course of high-dose rosuvastastin decreased the incidence of CIN and lower rate of death or nonfatal myocardial infarction at 6 month.
11. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98:59K–77.
12. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765–79.
13. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K–20.
14. Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol. 2010;6:679–88.
15. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007–15.
16. Khraibi AA, Knox FG. Effect of renal decapsulation on renal interstitial hydrostatic pressure and natriuresis. Am J Physiol. 1989;257:R44–8.
17. Lecian D, Demova H, Lodererova A, Zdychova J, Kluckova H, Teplan V, et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res. 2006;29:135–43.
18. Toth PP. An update on the benefits and risks of rosuvastatin therapy. Postgrad Med. 2014;126:7–17.
19. DiNicolantonio JJ, Lavie CJ, Serebruany VL, O’Keefe JH. Statin wars: the heavyweight match–atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013;125:7–16.
20. Schacter M. Chemical, pharmacokinetic and pharmacodynamics properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–25.
21. Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:17–33.
22. Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol. 2004;15:2502–3.
23. Quintavalle C, Flore D, De Micco F, Visconti G, Focaccio A, Golla B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126:3008–16.
24. Al-Otaibi KE, Al Elaiwi AM, Tariq M, Al-Asmari AK. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev. 2012;2012:831748.
25. Kwok CS, Pang CL, Yeong JK, Loke YK. Measures to treat contrast-induced nephropathy: overview of reviews. Br J Radiol. 2013;86:20120272.
26. Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography. Am J Med. 2014;127:987–1000. The largest and most updated meta-analysis of 15 randomized controlled trials showed that short-term statin exposure reduced the risk of CIN as compared to placebo and persisted in the group presenting in acute coronary syndromes with high-dose group but not in the low-dose group. Subgroup analyses also conferred benefit in patients with diabetes, chronic kidney disease, congestive heart failure, and those receiving >140 mL of contrast medium.
27. Liu Y, Liu YH, Tan N, Chen JY, Zhou YL, Li LW, et al. Comparision of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention. PLoS One. 2014;9:e111124. The first head-to-head trial comparing short-term pretreatment with rosuvastatin 10 mg to atorvastatin 20 mg in statin-naïve patients with CKD undergoing elective PCI and demonstrated similar efficacies in preventing CIN and longer term of all-cause mortality and major adverse cardiovascular events.
28. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007;49:1035–42.
29. Xie H, Ye Y, Shan G, Zhang S, Fang Q, Yang D, et al. Effect of statins in preventing contrast-induced nephropathy: an updated meta-analysis. Coron Artery Dis. 2014;25(7):565–74.
30. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009;104:519–24.
31. Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. J Thromb Thrombolysis. 2014;38:493–502.
32. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011;27:851–8.
33. Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012;122:195–202.
34. Jo S-H, Hahn J-Y, Lee SY, Kim HJ, Song YB, Choi JH, Choi SH, Lee SH, Gwon HC. High Dose Atorvastatin Pretreatment for Preventing Contrast-Induced Nephropathy in Patients Receiving Primary Percutaneous Coronary Intervention. J Cardiovasc Med. 2014. E-published ahead of print.
35. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61:711–4.
36. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501–10.
37. Brookhart MA, Solomon DH, Glynn RJ, Ridker PM. Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER trial. J Clin Pharmacol. 2011;51:1483–7.
38. Persson PB, Patzak A. Renal haemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydration. Nephrol Dial Transplant. 2005;20 Suppl 1:2–5.
39. Kim SJ, Salem MR, Joseph NJ, Madayag MA, Cavallino RP, Crystal GJ. Contrast media adversely affect oxyhemoglobin dissociation. Anesth Analg. 1990;71:73–6.